Steris PLC (STE) — SEC Filings

Q: What are the key financial highlights for Steris PLC?

Key financial highlights for Steris PLC are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Steris PLC?

Key executives at Steris PLC are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Steris PLC stock?

Risk factors for Steris PLC (STE) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Steris PLC?

Forward-looking statements and predictions from Steris PLC are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Steris PLC. Recent 8-K filing on Apr 6, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Steris PLC on SEC EDGAR

Overview

Steris PLC (STE) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 6, 2026: On April 6, 2026, STERIS plc filed an 8-K report detailing the departure of Director Thomas L. D. Sullivan. The filing also announced the appointment of new directors and changes in officer compensation arrangements, effective March 31, 2026. Specific details regarding the new compensation arrangeme

Sentiment Summary

Across 31 filings, the sentiment breakdown is: 3 bullish, 28 neutral. The dominant filing sentiment for Steris PLC is neutral.

Filing Type Overview

Steris PLC (STE) has filed 15 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 6 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (31)

STERIS plc Announces Director Departure and Officer Changes — 8-K · Apr 6, 2026 Risk: medium
On April 6, 2026, STERIS plc filed an 8-K report detailing the departure of Director Thomas L. D. Sullivan. The filing also announced the appointment of new dir
STERIS Q2 Earnings Soar on Strong Revenue Growth, Dental Divestiture Boosts Cash — 10-Q · Nov 6, 2025 Risk: low
STERIS plc reported robust financial performance for the three and six months ended September 30, 2025. Total revenues for the three months increased by 9.9% to
8-K Filing — 8-K · Nov 5, 2025
STERIS Q1 Revenue Climbs to $1.32B, Strategic Divestiture Underway — 10-Q · Aug 7, 2025 Risk: low
STERIS plc reported a robust first quarter for fiscal year 2026, with total revenue reaching $1.32 billion for the period ended June 30, 2025, an increase from
STERIS plc Files 8-K: Operations, Personnel, and Shareholder Matters — 8-K · Aug 6, 2025 Risk: medium
On July 31, 2025, STERIS plc filed an 8-K report detailing several key events. The company announced the results of its operations and financial condition, repo
STERIS plc Announces Executive Changes and Compensation Details — 8-K · Jul 3, 2025 Risk: medium
On July 1, 2025, STERIS plc announced changes in its executive team, including the departure of Director Michael S. Altorfer and the appointment of Dr. John T.
STERIS DEF 14A Details Executive Equity Compensation — DEF 14A · Jun 12, 2025 Risk: low
STERIS plc's DEF 14A filing, dated June 12, 2025, primarily details executive compensation for the fiscal years ending March 31, 2021, 2022, 2023, and 2024, rat
STERIS Posts Strong FY25 Growth, Net Income Jumps 18.6% — 10-K · May 29, 2025 Risk: medium
STERIS plc reported robust financial performance for the fiscal year ended March 31, 2025, with total revenue reaching $5.36 billion, marking a 7.8% increase fr
STERIS plc Files 8-K on Financials and Notes — 8-K · May 14, 2025 Risk: low
On May 14, 2025, STERIS plc filed an 8-K report detailing its financial condition and results of operations. The filing includes information on its common stock
STERIS plc Files 8-K: Other Event Notification — 8-K · Mar 3, 2025 Risk: low
On March 3, 2025, STERIS plc filed an 8-K report detailing an "Other Event." The filing does not contain specific financial figures or transaction details but s
STERIS plc Files Q3 FY25 10-Q Report — 10-Q · Feb 7, 2025 Risk: low
STERIS plc filed its 10-Q for the period ending December 31, 2024. The filing covers the third quarter of their fiscal year 2025. Key financial data and operati
STERIS plc Files 8-K on Financials — 8-K · Feb 5, 2025 Risk: low
On February 5, 2025, STERIS plc filed an 8-K report detailing its financial condition and results of operations. The filing includes information about its ordin
SC 13G/A Filing — SC 13G/A · Nov 8, 2024
STERIS plc Files 10-Q for Q2 FY2025 — 10-Q · Nov 7, 2024 Risk: low
STERIS plc reported its second quarter results for fiscal year 2025, ending September 30, 2024. The company's filing covers the period from April 1, 2024, to Se
STERIS plc Files 8-K on Financials — 8-K · Nov 6, 2024 Risk: low
STERIS plc filed an 8-K on November 6, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibi
SC 13G/A Filing — SC 13G/A · Oct 21, 2024
STERIS plc Issues $1.4 Billion in Senior Notes — 8-K · Oct 7, 2024 Risk: medium
On October 7, 2024, STERIS plc entered into a material definitive agreement related to the creation of a direct financial obligation. The company issued two ser
STERIS plc Q1 FY25 Earnings: Revenue Up Slightly to $1.49B — 10-Q · Aug 8, 2024 Risk: low
STERIS plc reported its first quarter results for fiscal year 2025, ending June 30, 2024. The company's revenue for the quarter was $1.49 billion, a slight incr
STERIS plc Files 8-K on Financials — 8-K · Aug 6, 2024 Risk: low
STERIS plc filed an 8-K on August 6, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits
STERIS plc Files 8-K on Shareholder Vote Matters — 8-K · Aug 1, 2024 Risk: low
On August 1, 2024, STERIS plc filed an 8-K report detailing a submission of matters to a vote of security holders. The filing indicates that STERIS plc, incorpo
STERIS plc Files DEF 14A on Executive Compensation — DEF 14A · Jun 12, 2024 Risk: low
STERIS plc filed a DEF 14A on June 12, 2024, detailing executive compensation and other corporate matters for the fiscal year ending March 31, 2024. The filing
STERIS Prices $1.4B Senior Notes Offering — 8-K · May 31, 2024 Risk: low
STERIS plc announced on May 31, 2024, that it has priced a public offering of $700 million aggregate principal amount of 7.000% senior notes due 2031 and $700 m
STERIS plc Files 2024 10-K Report — 10-K · May 29, 2024 Risk: medium
STERIS plc filed its 2024 10-K report, detailing its fiscal year ending March 31, 2024. The company, a leader in orthopedic, prosthetic, and surgical appliances
STERIS Prices $1.4B Senior Notes for Acquisition — 8-K · May 8, 2024 Risk: medium
On May 7, 2024, STERIS plc announced the pricing of two senior notes offerings: $700 million in aggregate principal amount of 5.000% senior notes due 2031 and $
STERIS plc Enters Material Definitive Agreement — 8-K · Apr 11, 2024 Risk: medium
On April 10, 2024, STERIS plc entered into a Material Definitive Agreement related to its STETwo700SeniorNotesDue2031 and Two700SeniorNotesDue2051. The filing a
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
BlackRock Amends STERIS plc Stake, Signals Continued Confidence — SC 13G/A · Feb 9, 2024 Risk: low
BlackRock Inc. filed an amended SC 13G/A on February 9, 2024, disclosing its ownership in STERIS plc as of December 31, 2023. This filing indicates that BlackRo
MFS Amends STERIS plc Stake to 8.00% as of Dec 29, 2023 — SC 13G/A · Feb 9, 2024 Risk: low
Massachusetts Financial Services Company (MFS) filed an amended SC 13G/A on February 9, 2024, reporting its ownership in STERIS plc. As of December 29, 2023, MF
STERIS plc Files 10-Q for Period Ending December 31, 2023 — 10-Q · Feb 8, 2024 Risk: medium
STERIS plc (STE) filed a Quarterly Report (10-Q) with the SEC on February 8, 2024. STERIS plc reported financial results for the period ending December 31, 2023
STERIS plc Files 8-K on Financial Results & Operations — 8-K · Feb 7, 2024
STERIS plc filed an 8-K on February 7, 2024, to report its results of operations and financial condition, along with financial statements and exhibits. This fil
WCM Investment Management Updates STERIS plc Stake (SC 13G/A) — SC 13G/A · Jan 30, 2024
WCM Investment Management, LLC, a Delaware-based investment firm, filed an amended SC 13G/A on January 30, 2024, indicating its ownership of STERIS plc (G8473T1

Risk Profile

Risk Assessment: Of STE's 25 recent filings, 0 were flagged as high-risk, 9 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Steris PLC's most recent 10-Q filing (Nov 6, 2025):

Revenue: $1,460.3M
Net Income: $191.9M
EPS: $1.94
Debt-to-Equity: 0.48
Cash Position: $319.2M
Operating Margin: 18.2%
Total Assets: $10,410.7M
Total Debt: $2,216.5M

Key Executives

Thomas L. D. Sullivan
Michael S. Altorfer
Dr. John T. Smith
Walter M. Rosebrough Jr.
Daniel J. Carestio

Industry Context

STERIS operates in the highly competitive healthcare and life sciences sectors, focusing on infection prevention and patient care. Key trends include increasing demand for advanced sterilization technologies, outsourced reprocessing services, and integrated operating room solutions. The industry is characterized by stringent regulatory oversight and a continuous need for innovation to meet evolving clinical needs and safety standards.

Top Tags

Medical Devices (5) · corporate-governance (4) · Healthcare (3) · Life Sciences (3) · financial-reporting (3) · 10-Q (3) · results-of-operations (3) · debt (3) · institutional-ownership (3) · amendment (3)

Executive Compensation

From the most recent DEF 14A filing (Jun 12, 2025):

Walter M. Rosebrough Jr. — Member
Daniel J. Carestio — Member

Key Numbers

Total Revenues (Q3 2025): $1,460.3M — Increased 9.9% from $1,328.9 million in Q3 2024.
Net Income Attributable to Shareholders (Q3 2025): $191.9M — Increased 27.9% from $150.0 million in Q3 2024.
Cash and Cash Equivalents (Sept 30, 2025): $319.2M — Increased from $171.7 million at March 31, 2025.
Net Cash Provided by Operating Activities (6 months ended Sept 30, 2025): $707.8M — Significant increase from $554.5 million in the prior year period.
Diluted EPS from Continuing Operations (Q3 2025): $1.94 — Increased from $1.51 in Q3 2024.
Proceeds from Dental Segment Sale: $787.5M — Total cash consideration for the divestiture of the Dental segment on May 31, 2024.
Long-term Indebtedness (Sept 30, 2025): $1,897.3M — Slight decrease from $1,918.7 million at March 31, 2025.
Ordinary Shares Outstanding (Nov 3, 2025): 98,147,009 — Reflects share repurchases during the period.
Repurchases of Ordinary Shares (6 months ended Sept 30, 2025): $111.1M — Demonstrates commitment to shareholder returns.
Cash Dividends Declared Per Share (Q3 2025): $0.63 — Increased from $0.57 in Q3 2024.
Total Revenue: $1.32B — Increased from $1.25B in Q1 2025, showing 5.6% growth.
Product Revenue: $700M — Grew from $660M in Q1 2025, indicating strong product demand.
Service Revenue: $620M — Increased from $590M in Q1 2025, reflecting robust service segment performance.
Period End Date: 2025-06-30 — Marks the end of the reported first fiscal quarter for 2026.
Dental Segment Classification Date: 2025-03-31 — Date the Dental segment was classified as discontinued operations.

Forward-Looking Statements

{"claim":"BlackRock will maintain a significant stake in STERIS plc throughout 2024.","entity":"BlackRock Inc.","targetDate":"2024-12-31","confidence":"medium"}
{"claim":"STERIS plc's stock price will experience continued stability due to institutional backing.","entity":"STERIS plc","targetDate":"2024-06-30","confidence":"low"}
{"claim":"MFS will maintain a significant stake in STERIS plc for the foreseeable future.","entity":"Massachusetts Financial Services Company","targetDate":"2025-02-09","confidence":"medium"}
{"claim":"STERIS plc will continue to show year-over-year growth in diluted EPS in its next quarterly report.","entity":"STERIS plc","targetDate":"2024-06-30","confidence":"medium"}

Related Companies

GETI B.ST · CMN · MDT · JNJ

Frequently Asked Questions

What are the latest SEC filings for Steris PLC (STE)?

Steris PLC has 31 recent SEC filings from Jan 2024 to Apr 2026, including 15 8-K, 6 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of STE filings?

Across 31 filings, the sentiment breakdown is: 3 bullish, 28 neutral. The dominant sentiment is neutral.

Where can I find Steris PLC SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Steris PLC (STE) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Steris PLC?

Key financial highlights from Steris PLC's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for STE?

The investment thesis for STE includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Steris PLC?

Key executives identified across Steris PLC's filings include Thomas L. D. Sullivan, Michael S. Altorfer, Dr. John T. Smith, Walter M. Rosebrough Jr., Daniel J. Carestio.

What are the main risk factors for Steris PLC stock?

Of STE's 25 assessed filings, 0 were flagged high-risk, 9 medium-risk, and 16 low-risk.

What are recent predictions and forward guidance from Steris PLC?

Recent forward-looking statements from Steris PLC include guidance on {"claim":"BlackRock will maintain a significant stake in STERIS plc throughout 2024.","entity":"BlackRock Inc.","targetD and 3 other predictions.